|
| First author [ref.] | Country | Year | Number (M/F) | Age (years) | LT types | MC (U/O) | Immunosuppressive agents | Study design | Cutoff for
LNR (> versus <) | Study endpoints | HR with 95% CI
(analysis methods) | Sources | Follow-up time (months) |
|
| Na [17] | Korea | 2014 | 224 (184/40) | Mean 51.9 ± 6.9 | LDLT | 141/83 | TAC/CyA + MMF + prednisolone | R | 6.0 (27/197) | OS, DFS | OS (M), 2.90 (1.40–6.00) | Direct | Median 68
(6–139) |
| DFS (M), 2.51 (0.99–6.39) | Direct |
|
| Shindoh [18] | Japan | 2014 | 124 (98/26) | Median 56 (37–67) | LDLT | 80/44 | TAC/CyA + steroid with/without MMF | R | 3.0 (61/62) | RFS | RFS (M), 1.26 (1.06–1.62) | Direct | Median 101.9
(3.5–165.4) |
|
| Xiao [19] | China | 2013 | 280 (249/31) | Mean 46.5 (20.5–69.1) | Mixed | NA | TAC/CyA + steroids with/without azathioprine and MMF | R | 4.0 (114/166) | OS, RFS, and 1/3/5 years OS/RFS | OS (M), 1.70 (1.16–2.47) | Direct | Mean 31.56
(13.2–144.0) |
| DFS (M), 1.76 (1.22–2.53) | Direct |
|
| Limaye [20] | America | 2013 | 160 (130/30) | Mean 55.4 | DDLT | 144/16 | TAC + steroid with/without MMF | R | 5.0 (28/132) | OS, DFS, and 1/3/5 years OS/RFS | OS (U), 2.12 (1.41–4.62) | Direct | Mean 38
(1–116) |
| RFS (U), 6.88 (2.99–16.20) | Direct |
|
| Motomura [21] | Japan | 2013 | 158 (92/66) | Mean 57 | LDLT | 94/64 | TAC/CyA + MMF | R | 4.0 (26/132) | OS, RFS, and 1/3/5 years OS/RFS | OS (U), 3.81 (2.26–6.41) | Curve | Median 40.3 |
| RFS (M), 6.24 (2.52–15.0) | Direct |
|
| Harimoto [22] | Japan | 2013 | 167 (NA/NA) | NA | LDLT | 105/62 | TAC/CyA + steroid and/or MMF | R | 4.0 (26/141) | RFS | RFS (U), 3.39 (1.73–6.62) | Data | Median 46.8 |
|
| Yoshizumi [23] | Japan |
2013 | 104 (63/41) | Median 58.0 (41–72) | LDLT | 52/52 | TAC/CyA + steroid and/or MMF | R | 4.0 (21/83) | RFS, 1/3/5 years RFS | RFS (M), 4.02 (1.38–11.6) | Direct | Median 57.9 |
|
| Wang [24] | China | 2011 | 101 (92/9) | Mean 48.4 (27–72) | DDLT | 36/65 | Calcineurin inhibitors and steroids | R | 3.0 (33/68) | OS, DFS, and 5 years OS/RFS | OS (U), 1.79 (1.30–2.46) | Curve | Mean 34.2
(4.56–74.64) |
| DFS (U), 2.18 (1.46–3.26) | Curve |
|
| Bertuzzo [25] | Italy | 2011 | 219 (186/33) | Median 57 (12–69) | DDLT | 138/81 | TAC/CyA (majority) | R | 5.0 (23/147) | OS, RFS, and 3/5 years OS/RFS | OS (M), 4.89 (2.47–9.58) | Direct | Median 40
(1–146) |
| RFS (M), 19.14 (6.95–52.71) | Direct |
|
| Halazun [26] | America | 2009 | 150 (119/31) | Mean 57.1 (29–74) | LDLT | 104/46 | TAC/CyA + steroid + MMF | R | 5.0 (13/137) | OS, DFS, and 1/3/5 years OS/DFS | OS (M), 6.10 (2.29–16.29) | Direct | Mean 37.2
(13.2–82.8) |
| DFS (M), 8.42 (2.85–24.88) | Direct |
|
